On Friday Mar. 21, Keith Krehbiel went from being the first human subject at the Stanford site of the international ADAPT-PD clinical study to becoming the first person in the U.S. to receive adaptive Deep Brain Stimulation (aDBS), a newly FDA-approved treatment for symptoms of Parkinson’s disease, as a part of his regular medical care. (Dai Sugano/Bay Area News Group)
On Friday Mar. 21, Keith Krehbiel went from being the first human subject at the Stanford site of the international ADAPT-PD clinical study to becoming the first person in the U.S. to receive adaptive Deep Brain Stimulation (aDBS), a newly FDA-approved treatment for symptoms of Parkinson’s disease, as a part of his regular medical care. (Dai Sugano/Bay Area News Group)
Two of the first patients of adaptive Deep Brain Sitimulation (aDBS) Parkinson's therapy and the neurologist who developed the care system share how life changes and how it doesn't when receiving the groundbreaking new FDA-approved treatment mitigating the most disruptive symptoms of the progressive neurological disease, which still has no cure.
Most Popular